English | Français
English | Français
iC BIOSOLUTIONS is developing a first-in-class secretome-based therapeutic platform designed to modulate inflammation and support tissue regeneration across multiple species.
Our strategy follows a stepwise, evidence-driven development pathway, beginning in veterinary medicine, where unmet medical needs are significant and clinical translation is faster, before expanding to additional species and indications.
The horse represents the initial and primary clinical application of our platform. Equine joint diseases, including osteoarthritis, constitute a major unmet medical need with few disease-modifying treatment options. Owing to their size, physiology, and accessible clinical follow-up, horses provide a highly relevant translational model for regenerative and anti-inflammatory therapies.
Importantly, horses naturally develop chronic joint degeneration that shares key biological, biomechanical, and inflammatory features with other mammalian species.
Our lead product, ICB001, is currently being developed to reduce lameness associated with non-septic joint diseases in horses.
This application allows iC BIOSOLUTIONS to:
This application provides an efficient and highly relevant pathway for initial clinical validation and market entry.
Beyond horses, the iC BIOSOLUTIONS platform is designed for direct extension to companion animals, including dogs and cats.
Chronic inflammatory and degenerative diseases are highly prevalent in pets, and current treatment options often remain largely symptomatic, with limited long-term efficacy or tolerability.
The biological mechanisms targeted by our secretomes (immunomodulation, tissue repair, and inflammatory control) are conserved across mammalian species.
Companion animals therefore represent a logical next step, leveraging:
Initial applications in companion animals will expand beyond joint diseases to selected severe chronic inflammatory conditions with limited therapeutic options. These programs are envisioned as near-to-mid-term extensions, building on the clinical and regulatory experience gained in equine medicine.
While iC BIOSOLUTIONS’ initial focus is veterinary medicine, the secretome platform itself is inherently translatable to human health.
Human applications will be developed as dedicated secretome-based products, leveraging a fully integrated and translatable development model (from cell sourcing and manufacturing to biological characterization and clinical validation), already demonstrated across large mammalian species.
This long-term vision is supported by: